Ascendis Stock Analysis

ASND
 Stock
  

USD 118.42  3.33  2.74%   

The latest price surge of Ascendis Pharma AS could raise concerns from shareholders as the firm is trading at a share price of 118.42 on 144,909 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.81. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Ascendis Pharma partners.
Please continue to Trending Equities.
  
The Ascendis Pharma stock analysis report makes it easy to digest most publicly released information about Ascendis Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ascendis Stock analysis module also helps to analyze the Ascendis Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Ascendis Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 8.46. Ascendis Pharma AS had not issued any dividends in recent years. Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Ascendis Pharma is traded on NASDAQ Exchange in the United States. For more info on Ascendis Pharma AS please contact Jan Mikkelsen at 45 70 22 22 44 or go to https://ascendispharma.com.

Ascendis Pharma AS Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ascendis Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ascendis Pharma AS or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ascendis Pharma AS appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 7.78 M. Net Loss for the year was (383.58 M) with profit before overhead, payroll, taxes, and interest of 4.25 M.
Ascendis Pharma AS currently holds about 955.15 M in cash with (417.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11.
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Ascendis Pharma ADR Earns Relative Strength Rating Upgrade - Investors Business Daily

Ascendis Pharma AS Upcoming and Recent Events

Earnings reports are used by Ascendis Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ascendis Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of March 2022
Next Financial Report26th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End9th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Ascendis Largest EPS Surprises

Earnings surprises can significantly impact Ascendis Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-03-22
2016-12-31-0.57-0.64-0.0712 
2016-11-30
2016-09-30-0.64-0.71-0.0710 
2016-08-31
2016-06-30-0.62-0.540.0812 
View All Earnings Estimates

Ascendis Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Ascendis Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Ascendis Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Ascendis Pharma AS specific information freely available to individual and institutional investors to make a timely investment decision.

Ascendis Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 6.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ascendis Pharma's market, we take the total number of its shares issued and multiply it by Ascendis Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ascendis Profitablity

Ascendis Pharma's profitability indicators refer to fundamental financial ratios that showcase Ascendis Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Ascendis Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ascendis Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ascendis Pharma's profitability requires more research than a typical breakdown of Ascendis Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.37) (0.40) 
Return on Average Equity(0.46) (0.47) 
Return on Invested Capital(0.72) (0.74) 
Return on Sales(48.86) (50.15) 

Management Efficiency

The entity has return on total asset (ROA) of (0.2658) % which means that it has lost $0.2658 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.6669) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma management efficiency ratios could be used to measure how well ascendis pharma as manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2022, Return on Average Assets is expected to decline to -0.4. In addition to that, Return on Average Equity is expected to decline to -0.47. Ascendis Pharma Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 805.89 Million. The current year Assets Non Current is expected to grow to about 301.1 M, whereas Tax Assets are forecasted to decline to about 1 M.
Last ReportedProjected for 2022
Book Value per Share 16.13  12.80 
Enterprise Value over EBIT(15.00) (16.18) 
Enterprise Value over EBITDA(15.83) (17.08) 
Price to Book Value 7.21  7.65 
Tangible Assets Book Value per Share 19.71  21.27 
Enterprise Value6.6 B5.5 B
Tangible Asset Value1.1 B1.2 B

Technical Drivers

As of the 2nd of December, Ascendis Pharma shows the risk adjusted performance of 0.2474, and Mean Deviation of 2.68. Ascendis Pharma AS technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Ascendis Pharma AS, which can be compared to its rivals. Please confirm Ascendis Pharma AS information ratio, and the relationship between the downside deviation and value at risk to decide if Ascendis Pharma AS is priced correctly, providing market reflects its regular price of 118.42 per share. Given that Ascendis Pharma has jensen alpha of 0.4722, we suggest you to validate Ascendis Pharma AS's prevailing market performance to make sure the company can sustain itself at a future point.

Ascendis Pharma AS Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Triangular Moving Average shows Ascendis Pharma double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Ascendis Pharma Technical and Predictive Indicators

Ascendis Pharma Forecast Models

Ascendis Pharma time-series forecasting models is one of many Ascendis Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ascendis Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ascendis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ascendis Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ascendis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Ascendis Pharma. By using and applying Ascendis Stock analysis, traders can create a robust methodology for identifying Ascendis entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(46.88) (48.12) 
Gross Margin 0.55  0.69 
Profit Margin(49.32) (50.61) 

Current Ascendis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ascendis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ascendis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
185.9Buy10Odds
Ascendis Pharma AS current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ascendis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ascendis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ascendis Pharma AS, talking to its executives and customers, or listening to Ascendis conference calls.
Ascendis Analyst Advice Details

Ascendis Stock Analysis Indicators

Ascendis Pharma AS stock analysis indicators help investors evaluate how Ascendis Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ascendis Pharma shares will generate the highest return on investment. By understating and applying Ascendis Pharma stock analysis, traders can identify Ascendis Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow584517000.00
Logo U R LimglogosUSASND.png
Common Stock Shares Outstanding54771763.00
Total Stockholder Equity883635000.00
DescriptionAscendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency . It also develops TransCon Growth Hormone for pediatric GHD in Japan TransCon hGH for adults with GHD TransCon parathyroid hormone for adult hypop
Total Cashflows From Investing Activities-110579000.00
Tax Provision-367000.00
Property Plant And Equipment Net126049000.00
Retained Earnings-1413855000.00
Cash And Short Term Investments682064000.00
Cash446267000.00
CodeASND
Accounts Payable59417000.00
Net Debt-341306000.00
50 Day M A112.3282
Total Current Liabilities100356000.00
Currency CodeUSD
Other Operating Expenses459570000.00
Non Current Assets Total279035000.00
Non Currrent Assets Other1808000.00
Please continue to Trending Equities. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for analysis

When running Ascendis Pharma AS price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Ascendis Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Quarterly Revenue Growth YOY
12.74
Return On Assets
(0.27) 
Return On Equity
(0.67) 
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Ascendis Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.